查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1698006

迷幻藥市場－全球產業規模、佔有率、趨勢、機會及預測，依藥物類型、應用、配銷通路、地區及競爭情況細分，2020-2030 年預測

Psychedelic Drug Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Drug Type, By Application, By Distribution Channel, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球迷幻藥市場價值為 45.5 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率將達到 10.55%。受臨床研究重大進展、監管框架不斷發展以及社會觀念轉變的推動，全球迷幻藥市場正經歷新一輪的興趣和擴張熱潮。精神健康障礙（尤其是憂鬱症、焦慮症和創傷後壓力症候群（PTSD））的盛行率不斷上升，迫切需要創新有效的治療方案。迷幻療法作為傳統抗憂鬱藥物的顛覆性替代品，正日益受到關注，並在臨床試驗中展現出快速起效和持續療效。

市場概覽
預測期 2026-2030
2024 年市場規模 45.5 億美元
2030年市場規模 83.2 億美元
2025-2030 年複合年成長率 10.55％
成長最快的領域 醫院藥房
最大的市場 北美洲

人們對心理健康的認知不斷提高、政策改革不斷進步以及越來越多的科學證據支持迷幻藥的醫療效用，進一步促進了市場成長。製藥公司、生技公司和研究機構之間的策略合作夥伴關係正在加速藥物開發流程，使迷幻化合物有可能融入精神病治療的主流領域。隨著監管部門批准的擴大和研發投入的加強，迷幻藥市場將實現長期大幅成長。

主要市場促進因素

精神健康障礙盛行率上升

主要市場挑戰

監管障礙

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球迷幻藥市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類型（麥角酸二乙醯胺、γ-羥基丁酸、氯胺酮、裸蓋菇素等）
    • 依應用（難治性憂鬱症、鴉片類藥物成癮、創傷後壓力症候群、發作性睡病、恐慌症等）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 產品市場圖
    • 依藥物類型
    • 按應用
    • 按配銷通路
    • 按地區

第6章：北美迷幻藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第7章：歐洲迷幻藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 法國
    • 義大利
    • 西班牙

第8章：亞太迷幻藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 日本
    • 印度
    • 澳洲
    • 韓國

第9章：南美洲迷幻藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲迷幻藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 合併與收購
  • 產品發布

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Jazz Pharmaceuticals PLC
  • NeonMind Biosciences Inc.
  • Cybin Inc.
  • Pfizer Inc
  • Numinus Wellness Inc
  • Mind Medicine Inc
  • PharmaTher Holdings Ltd
  • NRX Pharmaceuticals Inc
  • Seelos Therapeutics Inc
  • Revive Therapeutics Inc

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17524

Global Psychedelic Drug Market was valued at USD 4.55 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 10.55% through 2030. The global psychedelic drug market is witnessing a renewed surge in interest and expansion, fueled by significant advancements in clinical research, evolving regulatory frameworks, and shifting societal perceptions. The rising prevalence of mental health disorders-particularly depression, anxiety, and post-traumatic stress disorder (PTSD)-has created an urgent demand for innovative and effective treatment solutions. Psychedelic-based therapeutics are gaining traction as a disruptive alternative to conventional antidepressants, demonstrating both rapid onset and sustained efficacy in clinical trials.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.55 Billion
Market Size 2030USD 8.32 Billion
CAGR 2025-203010.55%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Market growth is being further catalyzed by increasing mental health awareness, progressive policy reforms, and a growing body of scientific evidence supporting the medical utility of psychedelics. Strategic partnerships between pharmaceutical companies, biotech firms, and research institutions are accelerating drug development pipelines, positioning psychedelic compounds for potential mainstream integration within psychiatric care. As regulatory approvals expand and investment in research and development intensifies, the psychedelic drug market is poised for substantial long-term growth.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The increasing global prevalence of mental health disorders is one of the most significant catalysts driving the growth of the psychedelic drugs market. As traditional treatment approaches struggle to meet the rising demand for effective solutions, psychedelic-assisted therapies are emerging as a disruptive innovation in psychiatric care. The burden of mental health disorders has reached unprecedented levels, with conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD) affecting millions worldwide. According to data from the World Health Organization (WHO), depression affects more than 284 million individuals worldwide, making it one of the most widespread mental health conditions. Similarly, over 264 million people are impacted by anxiety disorders, highlighting the growing demand for effective mental health interventions. Despite these alarming statistics, conventional treatments-including selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT)-often produce suboptimal results, with many patients experiencing delayed symptom relief, treatment resistance, or severe side effects. This growing treatment gap has created a strong demand for innovative therapies, positioning psychedelics as a viable alternative.

Key Market Challenges

Regulatory Hurdles

Perhaps the most significant challenge facing the psychedelic drug market is the complex and evolving regulatory landscape. Many psychedelics are classified as controlled substances due to their historical association with recreational use and concerns about safety and abuse potential. Navigating these regulations can be a lengthy and expensive process, often requiring years of clinical trials and regulatory approvals.

Key Market Players

  • Jazz Pharmaceuticals PLC
  • NeonMind Biosciences Inc.
  • Cybin Inc.
  • Pfizer Inc
  • Numinus Wellness Inc
  • Mind Medicine Inc
  • PharmaTher Holdings Ltd
  • NRX Pharmaceuticals Inc
  • Seelos Therapeutics Inc
  • Revive Therapeutics Inc

Report Scope:

In this report, the Global Psychedelic Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychedelic Drug Market, By Drug Type:

  • Lysergic Acid Diethylamide
  • Gamma Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Others

Psychedelic Drug Market, By Application:

  • Treatment-Resistant Depression
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Narcolepsy
  • Panic Disorders
  • Others

Psychedelic Drug Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Psychedelic Drug Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychedelic Drug Market.

Available Customizations:

Global Psychedelic Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychedelic Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 5.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Drug Type
    • 5.3.2. By Application
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Psychedelic Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 6.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Psychedelic Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Psychedelic Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Psychedelic Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Psychedelic Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 7.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Psychedelic Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Psychedelic Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. France Psychedelic Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Psychedelic Drug Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Psychedelic Drug Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Psychedelic Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 8.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Psychedelic Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Japan Psychedelic Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. India Psychedelic Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Australia Psychedelic Drug Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. South Korea Psychedelic Drug Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. South America Psychedelic Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 9.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Psychedelic Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Psychedelic Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Psychedelic Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Psychedelic Drug Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type (Lysergic Acid Diethylamide, Gamma Hydroxybutyric Acid, Ketamine, Psilocybin, Others)
    • 10.2.2. By Application (Treatment-Resistant Depression, Opiate Addiction, Post-Traumatic Stress Disorder, Narcolepsy, Panic Disorders, Others)
    • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Psychedelic Drug Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Psychedelic Drug Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Psychedelic Drug Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Jazz Pharmaceuticals PLC
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. NeonMind Biosciences Inc.
  • 14.3. Cybin Inc.
  • 14.4. Pfizer Inc
  • 14.5. Numinus Wellness Inc
  • 14.6. Mind Medicine Inc
  • 14.7. PharmaTher Holdings Ltd
  • 14.8. NRX Pharmaceuticals Inc
  • 14.9. Seelos Therapeutics Inc
  • 14.10. Revive Therapeutics Inc

15. Strategic Recommendations

16. About Us & Disclaimer